Bone Cancer Companies
Bone cancer encompasses various types, including primary bone cancers like osteosarcoma and Ewing sarcoma, as well as secondary bone cancers that metastasize from other parts of the body.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Â
Latest Bone Cancer Companies Update
BeiGene receives US FDA Breakthrough Therapy Designation for tislelizumab (an anti-PD-1 monoclonal antibody) for the treatment of locally advanced unresectable or metastatic osteosarcoma, potentially accelerating its pathway to market.
AstraZeneca's IMblaze 410 trial investigating Imfinzi (durvalumab) in combination with chemotherapy met its primary endpoint, showing improved overall survival in patients with stage III resectable osteosarcoma after surgery.
Seagen secures Fast Track designation from the US FDA for tucatinib (a HER2 tyrosine kinase inhibitor) in combination with other standard therapies for advanced bone cancer with HER2 alterations.
Eli Lilly and Innovent Biologics form a strategic partnership to develop and commercialize innovative therapies for bone cancer and other cancers. This collaboration combines their expertise and resources to accelerate drug development and market access.
Bristol-Myers Squibb and Checkmate Pharmaceuticals agree to co-develop and commercialize OPB-838, a novel drug candidate with potential for bone cancer treatment, leveraging their combined strengths in clinical development and commercialization.
List of Bone Cancer Key Companies in the Market
- Shanghai Henlius Biotech
- Zydus Pharmaceuticals
- Roxane Laboratories
- Baxter International Inc.
- Boehringer Ingelheim
- West-Ward Pharmaceuticals
- Perrigo Company
- Mylan Pharmaceuticals
- Fresenius Kabi USA LLC
- Amgen, Novartis Pharmaceuticals
- Amneal Pharmaceuticals
- Teva Pharmaceuticals
- Sandoz Inc.
- Jubilant Cadista Pharmaceuticals
Bone Cancer Market Highlights:
Bone Cancer Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
